SEC Form 4 · accession 0000886163-18-000121
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Higgins
Officer — Chief Executive Officer · Director
Period of report
Aug 16, 2018
Accepted (ET)
Aug 17, 2018 · 7:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 16, 2018 | M | 3,007 | $14.47 | A | 110,426 | D | |
| Common StockF1 | Aug 16, 2018 | S | 21,507 | $241.3289 | D | 88,919 | D | |
| Common StockF1 | Aug 17, 2018 | M | 12,993 | $14.47 | A | 101,912 | D | |
| Common StockF1 | Aug 17, 2018 | S | 12,993 | $243.00 | D | 88,919 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2 | $14.47 | Aug 16, 2018 | M | 3,007 | D | — | Feb 9, 2022 | Common Stock | 3,007 | 171,993 | D |
| Non-Qualified Stock Option (right to buy)F1,F2 | $14.47 | Aug 17, 2018 | M | 12,993 | D | — | Feb 9, 2022 | Common Stock | 12,993 | 159,000 | D |
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on June 22, 2018, in accordance with Rule 10b5-1.
- F2Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12.